

# Wu-Chou Su

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8595250/publications.pdf>

Version: 2024-02-01

260  
papers

21,679  
citations

24978

57  
h-index

10127

140  
g-index

263  
all docs

263  
docs citations

263  
times ranked

22348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2022, 12, 74-89.	7.7	133
2	Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 340-361.	4.6	15
3	Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR tyrosine kinase inhibitors. <i>Thoracic Cancer</i> , 2022, 13, 182-189.	0.8	3
4	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	0.5	70
5	FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer. <i>Scientific Reports</i> , 2022, 12, 241.	1.6	5
6	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. <i>Targeted Oncology</i> , 2022, 17, 1-13.	1.7	6
7	Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 430-430.	0.8	8
8	The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. <i>Scientific Reports</i> , 2022, 12, 3319.	1.6	7
9	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 170-177.	0.9	4
10	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
11	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9017-9017.	0.8	9
12	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9015-9015.	0.8	6
13	Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e567-e579.	1.9	3
14	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	3.2	21
15	The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	3
16	Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy. <i>Nanoscale</i> , 2021, 13, 8431-8441.	2.8	12
17	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. <i>Environment International</i> , 2021, 147, 105975.	4.8	12
18	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC. <i>Biomedicines</i> , 2021, 9, 243.	1.4	5
20	Development of the CK1B-resistant HER2-positive breast cancer cell line and xenograft animal models. <i>Cancer Medicine</i> , 2021, 10, 2370-2379.	1.3	0
21	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. <i>Scientific Reports</i> , 2021, 11, 4834.	1.6	1
22	Overcoming Radiation Resistance by Iron-Platinum Metal Alloy Nanoparticles in Human Copper Transport 1-Overexpressing Cancer Cells via Mitochondrial Disturbance. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2071-2085.	3.3	12
23	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9008-9008.	0.8	30
24	Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9007-9007.	0.8	24
25	Safety and Antitumor Activity of Î±-PD-L1 Antibody as Monotherapy or in Combination with Î±-TIM-3 Antibody in Patients with Microsatellite Instabilityâ€“High/Mismatch Repairâ€“Deficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29
26	Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. <i>Lung Cancer</i> , 2021, 158, 137-145.	0.9	6
27	Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100202.	0.6	3
28	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. <i>Frontiers in Oncology</i> , 2021, 11, 753788.	1.3	4
29	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100206.	0.6	3
30	EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1729-1739.	0.8	9
31	Development of a novel ALK rearrangement screening test for nonâ€“small cell lung cancers. <i>PLoS ONE</i> , 2021, 16, e0257152.	1.1	3
32	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	0.5	141
33	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced nonâ€“small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	1.3	24
34	Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. <i>Theranostics</i> , 2021, 11, 7029-7044.	4.6	37
35	Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS256-TPS256.	0.8	1
36	Firstâ€“line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutationâ€“positive nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 287-296.	0.8	3

#	ARTICLE	IF	CITATIONS
37	CD40 Pathway and IL-2 Expression Mediate the Differential Outcome of Colorectal Cancer Patients with Different CSF1R c.1085 Genotypes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12565.	1.8	4
38	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Diagnostics</i> , 2021, 11, 2308.	1.3	4
39	Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 760686.	1.3	8
40	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 452-459.	1.1	31
41	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. <i>Genomics</i> , 2020, 112, 1223-1232.	1.3	15
42	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of A Ceritinib in ALK-Positive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 609-617.	0.5	27
43	Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. <i>Frontiers in Neurology</i> , 2020, 11, 634.	1.1	51
44	Clinical Frailty Scale in Predicting Postoperative Outcomes in Older Patients Undergoing Curative Surgery for Urologic Malignancies: A Prospective Observational Cohort Study. <i>Urology</i> , 2020, 144, 38-45.	0.5	5
45	Ultra-Short Circulating Tumor DNA (uscDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2020, 12, 2041.	1.7	28
46	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	0.5	85
47	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. <i>Scientific Reports</i> , 2020, 10, 6774.	1.6	41
48	Electric Field-Induced Release and Measurement (EFIRM). <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1050-1062.	1.2	16
49	Silver-coated zero-valent iron nanoparticles enhance cancer therapy in mice through lysosome-dependent dual programmed cell death pathways: triggering simultaneous apoptosis and autophagy only in cancerous cells. <i>Journal of Materials Chemistry B</i> , 2020, 8, 4122-4131.	2.9	12
50	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1817-1826.	0.8	8
51	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	0.8	189
52	Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry. <i>Proteomics - Clinical Applications</i> , 2020, 14, e1900095.	0.8	7
53	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 373-386.	5.1	300
54	Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. <i>PLoS ONE</i> , 2020, 15, e0231413.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Phase 1 study of capmatinib in MET <sup>+</sup> positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
56	281 <sup>+</sup> JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC). , 2020, , .		2
57	Title is missing!. , 2020, 15, e0231413.		0
58	Title is missing!. , 2020, 15, e0231413.		0
59	Title is missing!. , 2020, 15, e0231413.		0
60	Title is missing!. , 2020, 15, e0231413.		0
61	Title is missing!. , 2020, 15, e0231413.		0
62	Title is missing!. , 2020, 15, e0231413.		0
63	Real <sup>+</sup> world outcomes of NSCLC patients receiving tissue or circulating tumor DNA <sup>+</sup> guided osimertinib treatment. <i>Cancer Medicine</i> , 2019, 8, 5939-5947.	1.3	12
64	Five Technologies for Detecting the EGFR T790M Mutation in the Circulating Cell-Free DNA of Patients With Non-small Cell Lung Cancer: A Comparison. <i>Frontiers in Oncology</i> , 2019, 9, 631.	1.3	20
65	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
66	Iron Release Profile of Silica-Modified Zero-Valent Iron NPs and Their Implication in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4336.	1.8	11
67	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non <sup>+</sup> Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6644-6652.	3.2	100
68	Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1892-1900.	0.5	16
69	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. <i>British Journal of Cancer</i> , 2019, 121, 131-138.	2.9	16
70	Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy <sup>+</sup> -based <sup>18</sup> F <sup>+</sup> FDG PET/CT in stage III non <sup>+</sup> small cell lung cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 151-159.	0.8	5
71	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 553-559.	0.5	123
72	Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC. <i>Medicine (United States)</i> , 2019, 98, e16766.	0.4	9

#	ARTICLE	IF	CITATIONS
73	Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 215-222.	0.8	68
74	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3011-3011.	0.8	14
75	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4117-4117.	0.8	63
76	miR-200c in extracellular vesicles as a circulating biomarker of EGFR-TKI response and a mediator of EGFR-TKI sensitivity in heterogeneous NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20547-e20547.	0.8	0
77	Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401875507.	1.4	13
78	Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. <i>Lung Cancer</i> , 2018, 120, 149-151.	0.9	1
79	Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumor-suppressing phenotype. <i>International Journal of Cancer</i> , 2018, 143, 1753-1763.	2.3	25
80	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
81	Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	13.9	3,530
82	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3101-3109.	0.8	252
83	Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 738-742.	1.2	24
84	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879758.	1.4	41
85	EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 126, 133-138.	0.9	33
86	Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. <i>Lung Cancer</i> , 2018, 125, 35-42.	0.9	28
87	Autophagy regulates vinorelbine sensitivity due to continued Keap1-mediated ROS generation in lung adenocarcinoma cells. <i>Cell Death Discovery</i> , 2018, 4, 33.	2.0	15
88	Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness. <i>Cell Death and Disease</i> , 2018, 9, 868.	2.7	25
89	Technical validation of the electric field-induced release and measurement (EFIRM) assay for the detection of EGFR mutations in circulating cell free DNA in plasma and saliva.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24172-e24172.	0.8	1
90	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. <i>PLoS ONE</i> , 2018, 13, e0192161.	1.1	26

#	ARTICLE	IF	CITATIONS
91	EFIRM liquid biopsy (eLB) detection of ultra-short circulating tumor DNA (uscDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, e24062-e24062.	0.8	2
92	Rasch models suggested the satisfactory psychometric properties of the World Health Organization Quality of Life™ Brief among lung cancer patients. Journal of Health Psychology, 2017, 22, 397-408.	1.3	37
93	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296.	0.8	470
94	Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713. Journal of Thoracic Oncology, 2017, 12, e72-e74.	0.5	4
95	Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways. Scientific Reports, 2017, 7, 3879.	1.6	12
96	Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis. Clinical Cancer Research, 2017, 23, 2335-2345.	3.2	40
97	Bimetallic nanoplasmonic gap-mode SERS substrate for lung normal and cancer-derived exosomes detection. Journal of the Taiwan Institute of Chemical Engineers, 2017, 80, 149-155.	2.7	45
98	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine, 2017, 5, 891-902.	5.2	92
99	The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages. Clinical Cancer Research, 2017, 23, 6021-6030.	3.2	16
100	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	0.5	21
101	Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan. Lung Cancer, 2017, 108, 183-191.	0.9	49
102	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 663-673.	2.5	24
103	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. Oncotarget, 2017, 8, 18590-18608.	0.8	52
104	Wheat germ agglutinin-induced paraptosis-like cell death and protective autophagy is mediated by autophagy-linked FYVE inhibition. Oncotarget, 2017, 8, 91209-91222.	0.8	12
105	Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget, 2017, 8, 30844-30858.	0.8	48
106	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.. Journal of Clinical Oncology, 2017, 35, 2006-2006.	0.8	17
107	Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020.	0.8	63
108	Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069.	0.8	12

#	ARTICLE	IF	CITATIONS
109	A phase I dose escalation study of SCB01A, a micro-tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy.. Journal of Clinical Oncology, 2017, 35, 2531-2531.	0.8	1
110	Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers.. Journal of Clinical Oncology, 2017, 35, 2580-2580.	0.8	5
111	Positive feedback regulation between IL10 and EGFR promotes lung cancer formation. Oncotarget, 2016, 7, 20840-20854.	0.8	28
112	Syntheses of Platinum-Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs. Chemistry - A European Journal, 2016, 22, 1926-1930.	1.7	9
113	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	1.4	50
114	Elucidating Quantum Confinement in Graphene Oxide Dots Based On Excitation-Wavelength-Independent Photoluminescence. Journal of Physical Chemistry Letters, 2016, 7, 2087-2092.	2.1	143
115	Cost effectiveness of cancer treatment in Taiwan. Journal of the Formosan Medical Association, 2016, 115, 609-618.	0.8	13
116	A Randomized Phase 2 Study Comparing the Combination of Ficlatusumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1736-1744.	0.5	46
117	Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice. Quality of Life Research, 2016, 25, 1441-1449.	1.5	15
118	Handheld energy-efficient magneto-optical real-time quantitative PCR device for target DNA enrichment and quantification. NPG Asia Materials, 2016, 8, e277-e277.	3.8	35
119	Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility. Journal of Biomedical Science, 2016, 23, 23.	2.6	16
120	Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs, 2016, 34, 625-635.	1.2	52
121	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	1.4	50
122	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	0.6	122
123	Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. PLoS ONE, 2016, 11, e0158125.	1.1	18
124	Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors.. Journal of Clinical Oncology, 2016, 34, 745-745.	0.8	0
125	Estrogen Receptor Gene Polymorphisms and Lung Adenocarcinoma Risk in Never-Smoking Women. Journal of Thoracic Oncology, 2015, 10, 1413-1420.	0.5	17
126	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	2.3	72



#	ARTICLE	IF	CITATIONS
127	The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	13
128	A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. <i>Oncotarget</i> , 2015, 6, 13671-13687.	0.8	26
129	Global Oct4 target gene analysis reveals novel downstream <i>PTEN</i> and <i>TNC</i> genes required for drug-resistance and metastasis in lung cancer. <i>Nucleic Acids Research</i> , 2015, 43, 1593-1608.	6.5	51
130	Antibody-free isolation of rare cancer cells from blood based on 3D lateral dielectrophoresis. <i>Lab on A Chip</i> , 2015, 15, 2950-2959.	3.1	84
131	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 793-799.	0.5	199
132	A novel dielectrophoresis-based microfluidic chip for antibody-free isolation of circulating tumor cells from blood. , 2015, , .		3
133	Comparison of expected health impacts for major cancers: Integration of incidence rate and loss of quality-adjusted life expectancy. <i>Cancer Epidemiology</i> , 2015, 39, 126-132.	0.8	8
134	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	5.1	1,369
135	Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA). <i>Human Genetics</i> , 2015, 134, 333-341.	1.8	34
136	Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis. <i>Supportive Care in Cancer</i> , 2015, 23, 283-291.	1.0	31
137	R331W Missense Mutation of Oncogene <i>YAP1</i> Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. <i>Journal of Clinical Oncology</i> , 2015, 33, 2303-2310.	0.8	77
138	AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699.	13.9	1,802
139	Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1427-1440.	1.5	36
140	Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 130-137.	1.1	29
141	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	0.5	138
142	ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALK- <i>negative</i> adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8060-8060.	0.8	51
143	Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8063-8063.	0.8	19
144	An increase in glucosylceramide synthase induces Bcl-xL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells. <i>Oncotarget</i> , 2015, 6, 20513-20524.	0.8	11

#	ARTICLE	IF	CITATIONS
145	Enhanced antitumor activity of rapamycin and genipin, a UCP-2 inhibitor, in lung cancer.. Journal of Clinical Oncology, 2015, 33, e13595-e13595.	0.8	0
146	Ipilimumab in treating Asian patient with advanced melanoma: The preliminary report of Taiwan ipilimumab extended access program group.. Journal of Clinical Oncology, 2015, 33, e20069-e20069.	0.8	0
147	Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget, 2014, 5, 740-753.	0.8	71
148	Estimation of loss of quality-adjusted life expectancy (QALE) for patients with operable versus inoperable lung cancer: Adjusting quality-of-life and lead-time bias for utility of surgery. Lung Cancer, 2014, 86, 96-101.	0.9	18
149	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	1.4	90
150	Noninvasive Saliva-based <i>EGFR</i> Gene Mutation Detection in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1117-1126.	2.5	146
151	An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer, 2014, 120, 976-982.	2.0	75
152	IL-6 as a potential biomarker in lung cancer. Lung Cancer Management, 2014, 3, 237-240.	1.5	0
153	A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 799-806.	1.1	14
154	CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. International Journal of Cancer, 2014, 135, 751-762.	2.3	8
155	Verification of Wild-Type EGFR Status in Non-Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases. Journal of Molecular Diagnostics, 2014, 16, 486-494.	1.2	15
156	Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells. Cancer Letters, 2014, 349, 144-151.	3.2	8
157	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. Oncology, 2014, 87, 104-113.	0.9	28
158	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. Journal of Clinical Oncology, 2014, 32, 2520-2520.	0.8	31
159	Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).. Journal of Clinical Oncology, 2014, 32, 4534-4534.	0.8	2
160	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <i>EGFR</i> -mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. Journal of Clinical Oncology, 2014, 32, 8017-8017.	0.8	31
161	Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. Oncotarget, 2014, 5, 6323-6337.	0.8	14
162	Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS2631-TPS2631.	0.8	0

#	ARTICLE	IF	CITATIONS
163	<i>EGFR</i> exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients. <i>International Journal of Cancer</i> , 2013, 132, 449-458.	2.3	12
164	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. <i>Cancer</i> , 2013, 119, 3043-3051.	2.0	19
165	The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1478-1485.	3.3	20
166	Estimating the lifelong health impact and financial burdens of different types of lung cancer. <i>BMC Cancer</i> , 2013, 13, 579.	1.1	21
167	STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production. <i>Angiogenesis</i> , 2013, 16, 207-222.	3.7	21
168	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	0.8	2,854
169	Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription-3 Activity Independently of the Liver Kinase B1-AMP-Activated Protein Kinase Pathway. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 241-250.	1.4	89
170	Risk factors for primary lung cancer among never smokers by gender in a matched case-control study. <i>Cancer Causes and Control</i> , 2013, 24, 567-576.	0.8	51
171	Gastric Perforation Secondary to Regression of Lung Adenocarcinoma After Gefitinib Treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, e6-e8.	0.8	9
172	An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan. <i>Oncology</i> , 2013, 84, 299-304.	0.9	3
173	Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non-Small Cell Lung Cancer in Never Smokers. <i>Cancer Research</i> , 2013, 73, 4028-4038.	0.4	53
174	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. <i>Carcinogenesis</i> , 2013, 34, 612-619.	1.3	15
175	Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1977-1985.	2.3	155
176	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. <i>Oncology</i> , 2013, 85, 44-52.	0.9	46
177	Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly (lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway. <i>International Journal of Nanomedicine</i> , 2013, 8, 2689.	3.3	16
178	Upregulation of Tissue Factor by Activated Stat3 Contributes to Malignant Pleural Effusion Generation via Enhancing Tumor Metastasis and Vascular Permeability in Lung Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e75287.	1.1	17
179	Betulinic Acid Decreases Specificity Protein 1 (Sp1) Level via Increasing the Sumoylation of Sp1 to Inhibit Lung Cancer Growth. <i>Molecular Pharmacology</i> , 2012, 82, 1115-1128.	1.0	80
180	Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2012, 264, 559-566.	3.6	216

#	ARTICLE	IF	CITATIONS
181	Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells. <i>Carcinogenesis</i> , 2012, 33, 2065-2075.	1.3	43
182	Annexin A2 Silencing Induces G2 Arrest of Non-small Cell Lung Cancer Cells through p53-dependent and -independent Mechanisms. <i>Journal of Biological Chemistry</i> , 2012, 287, 32512-32524.	1.6	64
183	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. <i>Nature Genetics</i> , 2012, 44, 1330-1335.	9.4	286
184	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 539-548.	5.1	390
185	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 528-538.	5.1	904
186	Constitutive STAT5 Activation Correlates With Better Survival in Cervical Cancer Patients Treated With Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 658-666.	0.4	13
187	Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. <i>Lung Cancer</i> , 2012, 75, 228-234.	0.9	71
188	Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. <i>Annals of Hematology</i> , 2012, 91, 1773-1778.	0.8	17
189	PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 4269.	3.3	123
190	Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer. <i>Journal of Solid Tumors</i> , 2012, 2, .	0.1	2
191	Nucleocytoplasmic transport blockage by SV40 peptide-modified gold nanoparticles induces cellular autophagy. <i>International Journal of Nanomedicine</i> , 2012, 7, 5215.	3.3	8
192	Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia. <i>Human Genetics</i> , 2012, 131, 1197-1203.	1.8	39
193	Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. <i>Biochemical Pharmacology</i> , 2012, 83, 1159-1171.	2.0	90
194	Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4007-4007.	0.8	50
195	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	0.8	74
196	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA7500-LBA7500.	0.8	60
197	Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 261-261.	0.8	22
198	Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. <i>Lung Cancer</i> , 2011, 71, 28-33.	0.9	73

#	ARTICLE	IF	CITATIONS
199	Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. <i>Lung Cancer</i> , 2011, 72, 280-286.	0.9	48
200	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. <i>PLoS ONE</i> , 2011, 6, e21428.	1.1	77
201	Cytomegalovirus and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 113-114.	0.8	4
202	Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1477-1484.	1.1	15
203	Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor- $\beta$ Expression in Lung Adenocarcinoma Cells. <i>Molecular Endocrinology</i> , 2011, 25, 1145-1158.	3.7	16
204	EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 2149-2158.	3.2	28
205	Germ Cell Tumor With Somatic-Type Malignancy Presenting As Right Facial Swelling in a Young Woman. <i>Journal of Clinical Oncology</i> , 2011, 29, e699-e701.	0.8	0
206	Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1066-1072.	0.5	45
207	Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1 $\alpha$ , GLUT1, and CAIX. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 53-61.	1.4	80
208	Single cell phospho-specific flow cytometry can detect dynamic changes of phospho-Stat1 level in lung cancer cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010, 77A, 1008-1019.	1.1	10
209	The down regulation of target genes by photo activated DNA nanoscissors. <i>Biomaterials</i> , 2010, 31, 6545-6554.	5.7	7
210	High Percentage of JAK2 Exon 12 Mutation in Asian Patients With Polycythemia Vera. <i>American Journal of Clinical Pathology</i> , 2010, 134, 266-270.	0.4	27
211	A Randomized, Double-blind, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron plus Dexamethasone Injection for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 294-301.	0.6	20
212	The 5p15.33 Locus Is Associated with Risk of Lung Adenocarcinoma in Never-Smoking Females in Asia. <i>PLoS Genetics</i> , 2010, 6, e1001051.	1.5	168
213	ATM polymorphisms and risk of lung cancer among never smokers. <i>Lung Cancer</i> , 2010, 69, 148-154.	0.9	45
214	Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. <i>Molecular Cancer</i> , 2010, 9, 309.	7.9	68
215	Ha-ras Oncogene-Induced Stat3 Phosphorylation Enhances Oncogenicity of the Cell. <i>DNA and Cell Biology</i> , 2009, 28, 131-139.	0.9	15
216	Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1 $\beta$ Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma. <i>Journal of Biological Chemistry</i> , 2009, 284, 9908-9916.	1.6	22

#	ARTICLE	IF	CITATIONS
217	Glycogen Synthase Kinase-3 and Omi/HtrA2 Induce Annexin A2 Cleavage followed by Cell Cycle Inhibition and Apoptosis. <i>Molecular Biology of the Cell</i> , 2009, 20, 4153-4161.	0.9	34
218	Interactive Effect of Cigarette Smoking With Human 8-Oxoguanine DNA N-Glycosylase 1 (hOGG1) Polymorphisms on the Risk of Lung Cancer: A Case-Control Study in Taiwan. <i>American Journal of Epidemiology</i> , 2009, 170, 695-702.	1.6	53
219	A Polymorphism in the <i>APE1</i> Gene Promoter is Associated with Lung Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 223-229.	1.1	75
220	Cytomegalovirus-related neutropenic enterocolitis with negative CMV antigenemia as the initial presentation in an acute myeloid leukemia patient. <i>Annals of Hematology</i> , 2009, 88, 279-280.	0.8	2
221	Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. <i>Lung Cancer</i> , 2009, 64, 251-256.	0.9	34
222	Angiogenic biomarkers in non-small cell lung cancer with malignant pleural effusion: Correlations with patient survival and pleural effusion control. <i>Lung Cancer</i> , 2009, 65, 371-376.	0.9	42
223	Targeted Paclitaxel by Conjugation to Iron Oxide and Gold Nanoparticles. <i>Journal of the American Chemical Society</i> , 2009, 131, 66-68.	6.6	177
224	The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas. <i>Annals of Hematology</i> , 2008, 87, 985-990.	0.8	11
225	A New Photothermal Therapeutic Agent: Core-Free Nanostructured Au <sub>100</sub> Ag <sub>100</sub> Dendrites. <i>Chemistry - A European Journal</i> , 2008, 14, 2956-2964.	1.7	79
226	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. <i>Lung Cancer</i> , 2008, 62, 78-84.	0.9	25
227	Oncogenic Ras-Induced Morphologic Change Is through MEK/ERK Signaling Pathway to Downregulate Stat3 at a Posttranslational Level in NIH3T3 Cells. <i>Neoplasia</i> , 2008, 10, 52-60.	2.3	19
228	Photoactive Compound-Triplex-Forming Oligonucleotide Linked Gold Nanoparticle as an Artificial Gene Specific DNA Cleaver Assembly. , 2008, , .		0
229	Facile Preparation of Self-Assembled Hydrogel-like GdPO <sub>4</sub> ·H <sub>2</sub> O Nanorods. <i>Langmuir</i> , 2008, 24, 8309-8313.	1.6	23
230	Modularly Assembled Magnetite Nanoparticles Enhance in Vivo Targeting for Magnetic Resonance Cancer Imaging. <i>Bioconjugate Chemistry</i> , 2008, 19, 1972-1979.	1.8	42
231	Nucleolin regulates c-Jun/Sp1-dependent transcriptional activation of cPLA <sub>2</sub> in phorbol ester-treated non-small cell lung cancer A549 cells. <i>Nucleic Acids Research</i> , 2007, 36, 217-227.	6.5	37
232	HER-2/neu raises SHP-2, stops IFN- $\beta$ anti-proliferation in bladder cancer. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 181-186.	1.0	11
233	Novel Arylhydrazone-Conjugated Gold Nanoparticles with DNA-Cleaving Ability: The First DNA-Nicking Nanomaterial. <i>Bioconjugate Chemistry</i> , 2007, 18, 1709-1712.	1.8	14
234	Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: Different cytogenetic changes are correlated with genders and smoking habits. <i>Lung Cancer</i> , 2007, 57, 292-301.	0.9	22

#	ARTICLE	IF	CITATIONS
235	Hormone replacement therapy and lung cancer risk in Chinese. <i>Cancer</i> , 2007, 110, 1768-1775.	2.0	53
236	Hypoxia-inducible factor-1 $\pm$ correlates with MET and metastasis in node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 167-175.	1.1	74
237	Water-Dissolvable Sodium Sulfate Nanowires as a Versatile Template for the Fabrication of Polyelectrolyte- and Metal-Based Nanotubes. <i>Journal of the American Chemical Society</i> , 2006, 128, 11606-11611.	6.6	48
238	Aqueous nickel-nitrilotriacetate modified Fe <sub>3</sub> O <sub>4</sub> •NH <sub>3</sub> <sup>+</sup> nanoparticles for protein purification and cell targeting. <i>Nanotechnology</i> , 2006, 17, 4174-4182.	1.3	33
239	Surfactant-Assisted Hollowing of Cu Nanoparticles Involving Halide-Induced Corrosion•Oxidation Processes. <i>Chemistry - A European Journal</i> , 2006, 12, 3805-3810.	1.7	37
240	Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1093-1100.	0.4	58
241	Expression of DNA repair gene Ku80 in lymphoid neoplasm. <i>European Journal of Haematology</i> , 2005, 74, 481-488.	1.1	9
242	Proteomic analysis of human pleural effusion. <i>Proteomics</i> , 2005, 5, 1062-1074.	1.3	75
243	Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 2222-2228.	3.2	135
244	Proteomic Profiling of Human Pleural Effusion Using Two-Dimensional Nano Liquid Chromatography Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2005, 4, 1274-1286.	1.8	72
245	Implantable venous port-related infections in cancer patients. <i>Supportive Care in Cancer</i> , 2004, 12, 197-201.	1.0	20
246	Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. <i>Annals of Hematology</i> , 2004, 83, 270-275.	0.8	80
247	Expression of S100A4 and <i>Met</i> : Potential Predictors for Metastasis and Survival in Early-Stage Breast Cancer. <i>Oncology</i> , 2004, 66, 429-438.	0.9	78
248	High-dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients with Nasopharyngeal Cancer: a Feasibility Study. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 331-335.	0.6	4
249	EBER-1 positive diffuse large cell lymphoma presenting as lupus nephritis. <i>Lupus</i> , 2003, 12, 486-489.	0.8	6
250	A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periapillary Carcinomas. <i>Chemotherapy</i> , 2003, 49, 154-158.	0.8	61
251	Combined Intrapleural and Intravenous Chemotherapy, and Pulmonary Irradiation, for Treatment of Patients with Lung Cancer Presenting with Malignant Pleural Effusion. <i>Oncology</i> , 2003, 64, 18-24.	0.9	32
252	Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. <i>Clinical Cancer Research</i> , 2003, 9, 2605-12.	3.2	23

#	ARTICLE	IF	CITATIONS
253	p53 and c-erbB-2 but Not bcl-2 are Predictive of Metastasis-free Survival in Breast Cancer Patients Receiving Post-mastectomy Adjuvant Radiotherapy in Taiwan. Japanese Journal of Clinical Oncology, 2002, 32, 332-339.	0.6	15
254	Successful Matched-Unrelated Bone Marrow Transplantation in a Patient With Beta-Thalassemia Major. Journal of Pediatric Hematology/Oncology, 2002, 24, 579-581.	0.3	4
255	Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Annals of Thoracic Surgery, 2001, 72, 1868-1876.	0.7	30
256	Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Digestive Diseases and Sciences, 2001, 46, 1387-1392.	1.1	35
257	Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma. Digestive Diseases and Sciences, 1998, 43, 2261-2266.	1.1	25
258	Using 2-step PCR and restriction endonuclease digestion to detect K-ras mutation in paraffin-embedded tissues: Is it reliable?. , 1998, 12, 168-171.		1
259	A Clinical Study of 130 Patients with Biliary Tract Cancers and Periapillary Tumors. Oncology, 1996, 53, 488-493.	0.9	20
260	Chemotherapy with Cisplatin and Continuous Infusion of 5-Fluorouracil and Bleomycin for Recurrent and Metastatic Nasopharyngeal Carcinoma in Taiwan. Oncology, 1993, 50, 205-208.	0.9	35